来源：康圣环球近日，康圣环球基因技术有限公司（“康圣环球”，9960.hk）宣布完成对上海真固生物科技有限公司（“真固生物”）90%股权的收购。这是继2024年战略性控股广州基准医疗后，康圣环球在实体瘤精准诊疗领域的又一关键落子。此次交易标志着康圣环球正式构建起覆盖肿瘤早筛早诊、伴随诊断、复发监测（MRD）三大核心环节的完整业务闭环，迈出从血液病龙头向泛肿瘤平台跃升的关键一步。近年来，多重政策与...
Source Link来源：康圣环球近日，康圣环球基因技术有限公司（“康圣环球”，9960.hk）宣布完成对上海真固生物科技有限公司（“真固生物”）90%股权的收购。这是继2024年战略性控股广州基准医疗后，康圣环球在实体瘤精准诊疗领域的又一关键落子。此次交易标志着康圣环球正式构建起覆盖肿瘤早筛早诊、伴随诊断、复发监测（MRD）三大核心环节的完整业务闭环，迈出从血液病龙头向泛肿瘤平台跃升的关键一步。近年来，多重政策与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.